Combination therapy with the type II anti-CD20 antibody obinutuzumab

被引:7
|
作者
Klein, Christian [1 ]
Bacac, Marina [1 ]
Umana, Pablo [1 ]
Fingerle-Rowson, Gunter [2 ]
机构
[1] Roche Innovat Ctr Zurich, Roche Pharmaceut Res & Early Dev, Zurich, Switzerland
[2] F Hoffmann Roche Ltd, Pharma Dev Clin Oncol, Basel, Switzerland
关键词
B-cell lymphoma; CD20; chronic lymphocytic leukemia; non-Hodgkin lymphoma; obinutuzumab; targeted therapy; CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; RITUXIMAB-REFRACTORY INDOLENT; BRUTONS TYROSINE KINASE; B-CELL MALIGNANCIES; FOLLICULAR LYMPHOMA; PLUS RITUXIMAB; MONOCLONAL-ANTIBODIES; ANTITUMOR-ACTIVITY; BTK INHIBITOR;
D O I
10.1080/13543784.2017.1373087
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody approved for first-line treatment of chronic lymphocytic leukemia (CLL) in combination with chlorambucil and for treatment of rituximab-refractory follicular lymphoma (FL). Areas covered: We describe current preclinical and clinical evidence supporting the combination of obinutuzumab with not only chemotherapy but also novel targeted therapies for B-cell hematologic malignancies, and its application in chemoimmunotherapy. We also provide an overview of the current clinical trial landscape investigating novel combination therapies based on obinutuzumab. Expert opinion: Within the next 10 years the treatment of B-cell malignancies with obinutuzumab is expected to increasingly move towards chemotherapy-free regimens. Novel combinations of obinutuzumab will be explored with targeted therapies, antibody-drug conjugates, and/or other immunotherapeutic agents, with the aim to achieve clinically meaningful improvements in efficacy and patient safety.
引用
收藏
页码:1145 / 1162
页数:18
相关论文
共 50 条
  • [1] The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
    Kuzniewska, Alicja
    Majeranowski, Alan
    Henry, Sara
    Kowalska, Daria
    Stasilojc, Grzegorz
    Urban, Aleksandra
    Zaucha, Jan M.
    Okroj, Marcin
    [J]. CANCERS, 2024, 16 (01)
  • [2] Acquisition of complement-dependent cytotoxicity by type II anti-CD20 therapeutic antibody obinutuzumab
    Kuzniewska, Alicja
    Majeranowski, Alan
    Kowalska, Daria
    Urban, Aleksandra
    Henry, Sara
    Okroj, Marcin
    [J]. MOLECULAR IMMUNOLOGY, 2022, 141 : 122 - 123
  • [3] Obinutuzumab: a new class of anti-CD20 monoclonal antibody
    Gagez, Anne-Laure
    Cartron, Guillaume
    [J]. CURRENT OPINION IN ONCOLOGY, 2014, 26 (05) : 484 - 491
  • [4] OBINUTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Apoptosis Inducer Oncolytic
    Karlin, L.
    Salles, G.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (09) : 657 - 662
  • [5] Experience with Obinutuzumab (Type II Anti-CD20) in Kidney Transplant Patients with Donor Specific Antibody (DSA plus ) Antibody Mediated Rejection
    Choi, J.
    Vo, A.
    Huang, E.
    Louie, S.
    Kang, A.
    Peng, A.
    Najjar, R.
    Jordan, S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 310 - 310
  • [6] Obinutuzumab, a new anti-CD20 antibody, is active and effective in anti-MAG antibody polyneuropathy.
    Briani, C.
    Visentin, A.
    Salvalaggio, A.
    Ruiz, M.
    Cacciavillani, M.
    Semenzato, G.
    Trentin, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 368 - 368
  • [7] Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations
    Illidge, Tim M.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 543 - 545
  • [8] OBINUTUZUMAB, A NEW ANTI-CD20 ANTIBODY, IS ACTIVE AND EFFECTIVE IN TWO PATIENTS WITH ANTI-MAG ANTIBODY POLYNEUROPATHY
    Salvalaggio, A.
    Visentin, A.
    Ruiz, M.
    Cacciavillani, M.
    Semenzato, G.
    Trentin, L.
    Briani, C.
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 : S40 - S41
  • [9] What signals are generated by anti-CD20 antibody therapy?
    Bonavida B.
    [J]. Current Hematologic Malignancy Reports, 2006, 1 (4) : 205 - 213
  • [10] Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia
    Shah, Arpita
    [J]. ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1356 - 1361